Photo taken from Francisco J. Esteva/LinkedIn
Jan 14, 2024, 15:07
Francisco J. Esteva: The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:
“The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story. From its discovery in the 1980s to the groundbreaking advancements in therapy, in this podcast I discuss the nuances of HER2 positive, negative, and the newly recognized HER2-Low category.
As we navigate the complexities of breast cancer, it is important to recognize how targeted therapies such as trastuzumab deruxtecan have transformed patient prognoses from the worst to some of the best outcomes in oncology.”
Proceed to video.
Source: Francisco J. Esteva/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14